Jörg Schüttrumpf

Prof. Jörg Schüttrumpf

Biotest AG
+1
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Blood
Verified
Journal Article
Closed access
VAValder R. Arruda
Valder R. Arruda
JSJoerg Schuettrumpf
Joerg Schuettrumpf
RHRoland W. Herzog
Roland W. Herzog
TNTimothy C. Nichols
Timothy C. Nichols
NRNancy Robinson
Nancy Robinson
KHKatherine A. High
Katherine A. High
Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal muscle, and have been used as gene delivery vehicles for hemophilia B and for muscular dystrophies in experimental animals and humans. Recent reports suggest that AAV vectors based on serotypes 1, 5, and 7 transduce murine skeletal muscle much more efficiently than AAV-2, with reported increases in expression ranging from 2-fold to 1000-fold. We sought to determine whether this increased efficacy could be observed in species other than mice. In immunodeficient mice we saw 10- to 20-fold higher levels of human factor IX (hF.IX) expression at a range of doses, and in hemophilic dogs we observed approximately 50-fold higher levels of expression. The increase in transgene expression was due partly to higher gene copy number and a larger number of cells transduced at each injection site. In all immunocompetent animals injected with AAV-1, inhibitory antibodies to F.IX developed, but in immunocompetent mice treated with high doses of vector, inhibitory antibodies eventually disappeared. These studies emphasize that the increased efficacy of AAV-1 vectors carries a risk of inhibitor formation, and that further studies will be required to define doses and treatment regimens that result in tolerance rather than immunity to F.IX.

15 March 2005 in Blood
Verified
Journal Article
Open access
PDF file
JSJoerg Schuettrumpf
Joerg Schuettrumpf
RHRoland W. Herzog
Roland W. Herzog
ASAlexander Schlachterman
Alexander Schlachterman
AKAntje Kaufhold
Antje Kaufhold
DSDarrel W. Stafford
Darrel W. Stafford
VAValder R Arruda
Valder R Arruda
Intramuscular injection of adeno-associated viral (AAV) vector to skeletal muscle of humans with hemophilia B is safe, but higher doses are required to achieve therapeutic factor IX (F.IX) levels. The efficacy of this approach is hampered by the retention of F.IX in muscle extracellular spaces and by the limiting capacity of muscle to synthesize fully active F.IX at high expression rates. To overcome these limitations, we constructed AAV vectors encoding F.IX variants for muscle- or liver-directed expression in hemophilia B mice. Circulating F.IX levels following intramuscular injection of AAV-F.IX-K5A/V10K, a variant with low-affinity to extracellular matrix, were 2-5 fold higher compared with wild-type (WT) F.IX, while the protein-specific activities remained similar. Expression of F.IX-R338A generated a protein with 2- or 6-fold higher specific activity than F.IX-WT following vector delivery to skeletal muscle or liver, respectively. F.IX-WT and variant forms provide effective hemostasis in vivo upon challenge by tail-clipping assay. Importantly, intramuscular injection of AAV-F.IX variants did not trigger antibody formation to F.IX in mice tolerant to F.IX-WT. These studies demonstrate that F.IX variants provide a promising strategy to improve the efficacy for a variety of gene-based therapies for hemophilia B.

24 November 2005 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ASA. Schlachterman
A. Schlachterman
JSJ. Schuettrumpf
J. Schuettrumpf
JLJ.-H. Liu
J.-H. Liu
CFC. F. Freguia
C. F. Freguia
RTR. Toso
R. Toso
VAValder R Arruda
Valder R Arruda

15 October 2002 in Journal of Virology
Verified
Journal Article
Open access
PDF file
FMFederico Mingozzi
Federico Mingozzi
JSJörg Schüttrumpf
Jörg Schüttrumpf
VAValder R. Arruda
Valder R. Arruda
YLYuhong Liu
Yuhong Liu
YLYi-Lin Liu
Yi-Lin Liu
RHRoland W. Herzog
Roland W. Herzog
Adeno-associated viral (AAV) vectors have been shown to direct stable gene transfer and expression in hepatocytes, which makes them attractive tools for treatment of inherited disorders such as hemophilia B. While substantial levels of coagulation factor IX (F.IX) have been achieved using AAV serotype 2 vectors, use of a serotype 5 vector further improves transduction efficiency and levels of F.IX transgene expression by 3- to 10-fold. In addition, the AAV-5 vector transduces a higher proportion of hepatocytes (∼15%). The subpopulations of hepatocytes transduced with either vector widely overlap, with the AAV-5 vector transducing additional hepatocytes and showing a wider area of transgene expression throughout the liver parenchyma.

1 June 2006 in Molecular Therapy
Verified
Journal Article
Open access
JSJoerg Schuettrumpf
Joerg Schuettrumpf
JLJian-Hua Liu
Jian-Hua Liu
LCLinda B Couto
Linda B Couto
KAKathakaly Addya
Kathakaly Addya
DLDebra G B Leonard
Debra G B Leonard
VAValder R Arruda
Valder R Arruda
The risk of germline transmission of vector sequences in humans is a major safety concern, because the enrollment of subjects of reproductive age in early-phase clinical trials of gene transfer continues to increase. In a study of adult men with hemophilia B, adeno-associated virus serotype 2 (AAV2) delivered to the liver via the hepatic artery resulted in unexpected transient vector dissemination to the semen. Here we report that intravenous AAV2 injection in rabbits proved a useful model to assess biologic parameters of vector dissemination to the semen. Detectable vector sequences in semen disappeared in a dose-dependent and time-dependent fashion. AAV infectious particles were present only as long as day 4 after injection and were undetectable thereafter. The kinetics of vector clearance was faster in the semen fractions enriched for motile sperm than in the total semen. In addition, increased frequency of semen sampling accelerated the clearance of vector sequences from semen. Long-term follow-up, spanning hundreds of spermatogenesis cycles, showed that there was no recurrence of detectable vector sequences in semen, thus reducing the probability of inadvertent transduction of early spermatogonia not committed to differentiation at the time of vector injection. We conclude that AAV2 presents minimal germline transmission risk for humans.

1 September 1997 in Thrombosis Research
Verified
Journal Article
Closed access
HWH.H. Watzke
H.H. Watzke
JSJörg Schüttrumpf
Jörg Schüttrumpf
SGS. Graf
S. Graf
KHK. Huber
K. Huber
SPS. Panzer
S. Panzer